Two Incretin Meds Pass Heart-Health Test
Two relatively new type 2 diabetes medications do not increase the risk for heart attack, stroke, or cardiovascular death, according to the results of two large heart-health studies. The medications saxagliptin (Onglyza) and alogliptin (Nesina) increase levels of incretin hormones, which in turn boost insulin production. Saxagliptin, however, was linked to hypoglycemia and an “unexpected” increased risk of hospitalization for heart failure, findings the researchers say merit additional study to confirm. No increased risk of pancreatic cancer was observed with either medication. Such large “outcomes studies” of the cardiovascular safety of new diabetes medications are now required by the Food and Drug Administration after the drugs are on the market.
Source: The New England Journal of Medicine, Oct. 3, 2013